| Combination of | |
|---|---|
| Testosterone propionate | Androgen; Anabolic steroid |
| Testosterone valerate | Androgen; Anabolic steroid |
| Testosterone undecylenate | Androgen; Anabolic steroid |
| Clinical data | |
| Trade names | Triolandren |
| Other names | TP/TV/TUe |
| Routes of administration | Intramuscular injection |
Testosterone propionate/testosterone valerate/testosterone undecylenate (TP/TV/TUe), sold under the brand name Triolandren, is an injectable combination medication of testosterone propionate (TP), testosterone valerate (TV), and testosterone undecylenate (TUe), which are all androgens/anabolic steroids. It contains 20 mg/mL TP, 80 mg/mL TV, and 150 mg/mL TUe (for a total of 250 mg testosterone ester and 173.8 mg free testosterone) in oil solution and is administered by intramuscular injection at regular intervals. The medication has been reported to have a duration of action of about 10 to 20 days.
| Medication | Form | Major brand names | Duration |
|---|---|---|---|
| Testosterone | Aqueous suspension | Andronaq, Sterotate, Virosterone | 2–3 days |
| Testosterone propionate | Oil solution | Androteston, Perandren, Testoviron | 3–4 days |
| Testosterone phenylpropionate | Oil solution | Testolent | 8 days |
| Testosterone isobutyrate | Aqueous suspension | Agovirin Depot, Perandren M | 14 days |
| Mixed testosterone esters | Oil solution | Triolandren | 10–20 days |
| Mixed testosterone esters | Oil solution | Testosid Depot | 14–20 days |
| Testosterone enanthate | Oil solution | Delatestryl | 14–28 days |
| Testosterone cypionate | Oil solution | Depovirin | 14–28 days |
| Mixed testosterone esters | Oil solution | Sustanon 250 | 28 days |
| Testosterone undecanoate | Oil solution | Aveed, Nebido | 100 days |
| Testosterone buciclate | Aqueous suspension | 20 Aet-1, CDB-1781 | 90–120 days |
| Nandrolone phenylpropionate | Oil solution | Durabolin | 10 days |
| Nandrolone decanoate | Oil solution | Deca Durabolin | 21–28 days |
| Methandriol | Aqueous suspension | Notandron, Protandren | 8 days |
| Methandriol bisenanthoyl acetate | Oil solution | Notandron Depot | 16 days |
| Metenolone acetate | Oil solution | Primobolan | 3 days |
| Metenolone enanthate | Oil solution | Primobolan Depot | 14 days |
| Note: All are via i.m. injection. Footnotes: = TP, TV, and TUe. = TP and TKL. = TP, TPP, TiCa, and TD. = Studied but never marketed. = Developmental code names. Sources: See template. | |||
See also
- Testosterone propionate/testosterone enanthate/testosterone undecylenate
- List of combined sex-hormonal preparations § Androgens
References
- ^ Schuermann H, Doepfmer R (1960). Fertilitätsstörungen beim Manne. Springer-Verlag. pp. 260–. ISBN 978-3-642-94784-1.
- ^ Ufer J (1960). Hormontherapie in der Frauenheilkunde: Grundlagen und Praxis. Gruyter. p. 153. ISBN 9783111138770.
- ^ Aakvaag A, Vogt JH (March 1969). "Plasma testosterone values in different forms of testosterone treatment". Acta Endocrinologica. 60 (3): 537–42. doi:10.1530/acta.0.0600537. PMID 5395873.
Triolandren®, for intramuscular use, kindly supplied by Ciba, Basel, through Kobro 8c Co., Oslo, containing three different testosterone esters, in the following amounts of testosterone equivalents per ml oil: propionate 20 mg; valerate 80 mg; undecylenate 150 mg.
- Zachmann M, Prader A (January 1970). "Anabolic and androgenic effect of testosterone in sexually immature boys and its dependency on growth hormone". The Journal of Clinical Endocrinology and Metabolism. 30 (1): 85–95. doi:10.1210/jcem-30-1-85. PMID 4311616.
Triolandren, CIBA; 250 mg of this preparation contains 20 mg of testosterone propionate, 80 mg of testosterone-n-valerianate, and 150 mg of testoster- one undecylenate—250 mg thus contains 173.8 mg of testosterone; the remaining 76.2 mg consists of the ester components
| Androgen receptor modulators | |||||||
|---|---|---|---|---|---|---|---|
| ARTooltip Androgen receptor |
| ||||||
| GPRC6A |
| ||||||
 | This drug article relating to the genito-urinary system is a stub. You can help Misplaced Pages by expanding it. |